There is evidence that elevated tissue concentrations of glutamate may contribute to pain and sensitivity in certain musculoskeletal pain conditions. In the present study, the food additive monosodium glutamate (MSG) was injected intravenously into rats to determine whether it could significantly elevate interstitial concentrations of glutamate in the masseter muscle and whether MSG administration could excite and/or sensitize slowly conducting masseter afferent fibers through N-methyl-D-aspartate (NMDA) receptor activation. The interstitial concentration of glutamate after systemic injection of isotonic phosphate-buffered saline (control) or MSG (10 and 50 mg/kg) was measured with a glutamate-selective biosensor. The pre-injection baseline interstitial concentration of glutamate in the rat masseter muscle was 24 ± 11 lM. Peak interstitial concentration after injection of 50 mg/kg MSG was 63 ± 18 lM and remained elevated above baseline for $18 min. In vivo single unit recording experiments were undertaken to assess the effect of MSG (50 mg/kg) on masseter afferent fibers. Injection of MSG evoked a brief discharge in one afferent fiber, and significantly decreased ($25%) the average afferent mechanical threshold (n = 10) during the first 5 min after injection of MSG. Intravenous injection of ketamine (1 mg/kg), 5 min prior to MSG, prevented the MSG-induced decreases in the mechanical threshold of masseter afferent fibers. The present results indicate that a 2-to 3-fold elevation in interstitial glutamate levels in the masseter muscle is sufficient to excite and induce afferent mechanical sensitization through NMDA receptor activation. These findings suggest that modest elevations of interstitial glutamate concentration could alter musculoskeletal pain sensitivity in humans. Ó
Introduction
Monosodium glutamate (MSG) is a food additive that is currently considered to be without serious safety concerns (Filer and Stegink, 1994) . Initially, elevated consumption of MSG was linked to the symptoms such as headache, burning sensations, facial pressure and chest tightness (Schaumburg et al., 1969) . More recent work has failed to evoke these symptoms consistently in healthy subjects after ingestion of large doses of MSG, even in individuals believed to be sensitive to MSG (Geha et al., 2000a,b) . However, it is not known whether elevated tissue levels of glutamate alter sensory perception even in subjects who do not report adverse symptoms or overt pain after systemic administration of MSG.
